{"retracted":false,"update":{"timestamp":1480464000000,"doi":"10.1186/s13045-016-0364-0","type":"correction"},"doi":"10.1186/s13045-015-0215-4","journal":"Journal of Hematology & Oncology","publisher":"Springer Nature","title":"Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Childrenâ€™s Oncology Group"}
